Chronic Lymphocytic Leukemia

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes. This article was supported in part by Eli Lilly. Content independently developed and published by OncLive.

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.